MAZE

Business Context and Reporting Period

Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, including obesity, using its proprietary Compass platform. This Form 10-Q covers the quarterly period ended June 30, 2025. The company completed its Initial Public Offering (IPO) in February 2025, transitioning from a private entity with redeemable convertible preferred stock to a public company with common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Shift: The company recognized no revenue in Q2 2025, compared to $165.0 million in Q2 2024. The 2024 revenue was driven by one-time upfront payments from license agreements with Shionogi ($150 million), Trace Neuroscience ($15 million), and Neurocrine ($2.5 million).
• Profitability Reversal: The company swung from a net income of $139.1 million in Q2 2024 to a net loss of $33.7 million in Q2 2025, primarily due to the absence of license revenue and increased operating costs.
• Expense Growth: Operating expenses increased by 43% year-over-year for the quarter (from $25.4 million to $36.5 million). Research and Development (R&D) expenses rose $8.6 million, driven by the progression of Phase 2 trials for MZE829 and Phase 1 trials for MZE782.
• Capital Structure: In February 2025, the company completed its IPO, issuing 8.75 million shares at $16.00 per share for net proceeds of approximately $127.8 million. All outstanding redeemable convertible preferred stock converted to common stock upon the IPO.

Guidance, Outlook, and Risks

• Liquidity: As of June 30, 2025, the company held $264.5 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least one year from the filing date.
• Development Milestones:
  • MZE829: Phase 2 trial initiated in November 2024; first patient dosed in February 2025. Initial proof of concept data is expected in Q1 2026.
  • MZE782: Phase 1 trial initiated in September 2024. Initial proof of concept data for phenylketonuria (PKU) and chronic kidney disease (CKD) is expected in Q3 2025.
• Future Funding: The company expects to incur significant and increasing losses for the foreseeable future and will require substantial additional capital to advance clinical trials and commercialization efforts.
• Key Risks:
  • Development Risk: High uncertainty regarding clinical trial outcomes, patient enrollment (particularly for genetically defined populations), and regulatory approval.
  • Third-Party Reliance: Dependence on third-party CROs and CMOs (including WuXi Apptec in China) for manufacturing and trials, exposing the company to supply chain and geopolitical risks (e.g., BIOSECURE Act).
  • Intellectual Property: Risks related to the protection of the Compass platform and therapeutic candidates, including potential infringement claims or failure to secure patents.

Investor Verification Checklist

• Verify the specific timeline and enrollment status of the MZE829 Phase 2 and MZE782 Phase 1 clinical trials.
• Confirm the company's cash burn rate and runway given the absence of recurring revenue streams.
• Review the terms of the Shionogi, Trace, and Neurocrine license agreements to understand potential future milestone payments and royalty structures.
• Assess the impact of the BIOSECURE Act and other trade restrictions on the company's reliance on Chinese contract manufacturers.
• Monitor the company's ability to raise additional capital in the current market environment to sustain operations beyond the 12-month liquidity horizon.